


Amendments to the Claims

1. (Currently amended) A method of treating depression or pain in a mammal comprising administering to a mammal in need of such treatment an effective amount of a

[A] compound of formula (I)



(I)

wherein

n is 1, 2 or 3;

R1 is C₂-C₁₀alkyl, C₂-C₁₀alkenyl, C₃-C₈cycloalkyl, C₃-C₈cycloalkenyl, C₄-C₁₀cycloalkylalkyl or C₄-C₁₀cycloalkenylalkyl wherein one -CH₂- within any cycloalkyl moiety is optionally substituted by -O- or -S- and wherein each group is optionally substituted with from 1 to 7 halogen substituents and/or with from 1 to 3 substituents each independently selected from hydroxy, cyano, C₁-C₄alkyl, C₁-C₄alkylthio (optionally substituted with from 1 to 3 halogen atoms) and C₁-C₄alkoxy (optionally substituted with from 1 to 3 halogen atoms);

R2 is independently at each occurrence selected from H and C₁-C₄alkyl;

R3 is H or C₁-C₄alkyl;

R4 is H, halogen, hydroxy, cyano, C₁-C₄alkyl or C₁-C₄alkoxy;

R5 is H, halogen, hydroxy, cyano, C₁-C₄alkyl or C₁-C₄alkoxy; and

Heteroaryl is


- (i) a 5- or 6-membered monocyclic heteroaromatic group optionally substituted with 1, 2, 3 or 4 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C₁-C₄alkyl (optionally substituted with 1, 2 or 3 F atoms), C₁-C₄alkoxy (optionally substituted with 1, 2 or 3 F atoms) and C₁-C₄alkylthio (optionally substituted with 1, 2 or 3 F atoms) and/or with

1 substituent selected from pyridinyl, pyrazolyl, phenyl (optionally substituted with 1, 2 or 3 halo substituents), benzyl (optionally substituted with 1, 2 or 3 halo substituents) and phenoxy (optionally substituted with 1, 2 or 3 halo substituents) with the proviso that only C₁-C₄alkyl may be a substituent for the H of any -NH- moiety present within the group, or

- (ii) an 8-, 9- or 10-membered bicyclic heteroaromatic group optionally substituted with 1, 2, 3, 4, 5 or 6 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C₁-C₄alkyl (optionally substituted with 1, 2 or 3 F atoms), C₁-C₄alkoxy (optionally substituted with 1, 2 or 3 F atoms) and C₁-C₄alkylthio (optionally substituted with 1, 2 or 3 F atoms) with the proviso that only C₁-C₄alkyl may be a substituent for the H of any -NH- moiety present within the group;

or a pharmaceutically acceptable salt thereof [for use in a method for treatment of the human or animal body by therapy].

2. (Original) A compound of formula (I)



wherein

n is 1, 2 or 3;

R₁ is C₂-C₁₀alkyl, C₂-C₁₀alkenyl, C₃-C₈cycloalkyl, C₃-C₈cycloalkenyl,

C₄-C₁₀cycloalkylalkyl or C₄-C₁₀cycloalkenylalkyl wherein one -CH₂-

within any cycloalkyl moiety is optionally substituted by -O- or -S- and

wherein each group is optionally substituted with from 1 to 7 halogen

substituents and/or with from 1 to 3 substituents each independently selected

from hydroxy, cyano, C₁-C₄alkyl, C₁-C₄alkylthio (optionally substituted with

from 1 to 3 halogen atoms) and C₁-C₄alkoxy (optionally substituted with from 1 to 3 halogen atoms);

R₂ is independently at each occurrence selected from H and C₁-C₄alkyl;

R₃ is H or C₁-C₄alkyl;


R₄ is H, halogen, hydroxy, cyano, C₁-C₄alkyl or C₁-C₄alkoxy;

R₅ is H, halogen, hydroxy, cyano, C₁-C₄alkyl or C₁-C₄alkoxy; and

Heteroaryl is

- (i) a 5- or 6-membered monocyclic heteroaromatic group optionally substituted with 1, 2, 3 or 4 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C₁-C₄alkyl (optionally substituted with 1, 2 or 3 F atoms), C₁-C₄alkoxy (optionally substituted with 1, 2 or 3 F atoms) and C₁-C₄alkylthio (optionally substituted with 1, 2 or 3 F atoms) and/or with 1 substituent selected from pyridinyl, pyrazolyl, phenyl (optionally substituted with 1, 2 or 3 halo substituents), benzyl (optionally substituted with 1, 2 or 3 halo substituents) and phenoxy (optionally substituted with 1, 2 or 3 halo substituents) with the proviso that only C₁-C₄alkyl may be a substituent for the H of any -NH- moiety present within the group, or
- (ii) an 8-, 9- or 10-membered bicyclic heteroaromatic group optionally substituted with 1, 2, 3, 4, 5 or 6 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C₁-C₄alkyl (optionally substituted with 1, 2 or 3 F atoms), C₁-C₄alkoxy (optionally substituted with 1, 2 or 3 F atoms) and C₁-C₄alkylthio (optionally substituted with 1, 2 or 3 F atoms) with the proviso that only C₁-C₄alkyl may be a substituent for the H of any -NH- moiety present within the group;

or a pharmaceutically acceptable salt thereof, with the proviso that the compounds



are excluded.

3. (Currently amended) A compound as claimed in [Claim 1 or] Claim 2 wherein n is 1.
4. (Currently amended) A compound as claimed in [any preceding] Claims 2 or 3 wherein R2 [is H], R3 [is H], R4 [is H] and R5 [is] are H.
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Currently amended) A compound as claimed in any one of Claims [1 to 7] 2 or 3 wherein R1 is C₂-C₁₀alkyl optionally substituted with from 1 to 7 halogen substituents and/or with from 1 to 3 substituents each independently selected from hydroxy, cyano, C₁-C₄alkyl, C₁-C₄alkylthio (optionally substituted with from 1 to 3 halogen atoms) and C₁-C₄alkoxy (optionally substituted with from 1 to 3 halogen atoms).
9. (Currently amended) A compound as claimed in any one of Claims [1 to 7] 2 or 3 wherein R1 is C₄-C₁₀cycloalkylalkyl wherein one -CH₂- within the cycloalkyl moiety is optionally substituted by -O- or -S- and wherein the group is optionally substituted with from 1 to 7 halogen substituents and/or with from 1 to 3 substituents each independently selected from hydroxy, cyano, C₁-C₄alkyl, C₁-C₄alkylthio (optionally substituted with from 1 to 3 halogen atoms) and C₁-C₄alkoxy (optionally substituted with from 1 to 3 halogen atoms).
10. (Currently amended) A compound as claimed in any one of Claims [1 to 9] 2 or 3 wherein Heteroaryl is a 5- or 6-membered monocyclic heteroaromatic group

optionally substituted with 1, 2, 3 or 4 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C₁-C₄alkyl (optionally substituted with 1, 2 or 3 F atoms), C₁-C₄alkoxy (optionally substituted with 1, 2 or 3 F atoms) and C₁-C₄alkylthio (optionally substituted with 1, 2 or 3 F atoms) and/or with 1 substituent selected from pyridinyl, pyrazolyl, phenyl (optionally substituted with 1, 2 or 3 halo substituents), benzyl (optionally substituted with 1, 2 or 3 halo substituents) and phenoxy (optionally substituted with 1, 2 or 3 halo substituents) with the proviso that only C₁-C₄alkyl may be a substituent for the H of any -NH- moiety present within the group.

11. (Canceled)

12. (Canceled)

13. (Currently amended) A compound as claimed in any one of Claims [1 to 9] 2 or 3 wherein Heteroaryl is an 8-, 9- or 10-membered bicyclic heteroaromatic group optionally substituted with 1, 2, 3, 4, 5 or 6 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C₁-C₄ alkyl (optionally substituted with 1, 2 or 3 F atoms), C₁-C₄alkoxy (optionally substituted with 1, 2 or 3 F atoms) and C₁-C₄thioalkyl (optionally substituted with 1, 2 or 3 F atoms) with the proviso that only C₁-C₄alkyl may be a substituent for the H of any -NH- moiety present within the group.

14. (Canceled)

15. (Canceled)

16. (Currently amended) A pharmaceutical composition comprising a compound of formula (I) as defined in Claim [1] 2, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent, excipient or carrier.

17. (Canceled)

18. (Canceled)